Mesenchymal stem cell-derived exosome: A tumor regulator and carrier for targeted tumor therapy. (1st February 2022)

• Record Type: Journal Article
• Authors: Zhang, Fusheng; Guo, Jinshuai; Zhang, Zhenghou; Qian, Yiping; Wang, Guang; Duan, Meiqi; Zhao, Haiying; Yang, Zhi; Jiang, Xiaofeng
• Is Part Of: Cancer letters. Volume 526(2022)
• Page Start: 29
• Page End: 40
• Publication Date: 2022-02-01
• Subjects: Mesenchymal stem cells -- Immunomodulatory -- Tumor associated MSCs-derived exosomes -- Drug delivery -- Targeted tumor therapy; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2021.11.015
• Languages: English
• ISSNs: 0304-3835

Abstract

Abstract: Mesenchymal stem cells (MSCs) are multipotent stromal cells that have the ability to differentiate into multiple cell types. Several studies have shown that exosomes secreted by MSCs (MSCs-Exo) play an important role in tumor growth, angiogenesis, invasion, and drug resistance. However, contradictory results have suggested that MSCs-Exo can also suppress tumors through specific mechanisms, such as regulating immune responses and intercellular signaling. Consequently, the relationship between MSCs-Exo and tumors remains controversial. However, it is undeniable that exosomes, as natural vesicles, can be excellent drug carriers and show promise for application in targeted tumor therapy. Here, we review the current knowledge regarding the involvement of MSCs-Exo in tumor progression and their potential as drug delivery systems in targeted therapy. We argue that MSCs‐Exo can be used as safe carriers of antitumor drugs. Highlights: MSCs-Exo can regulate tumor progression through tumor microenvironment remodeling. MSCs-Exo can be used for targeted tumor therapy by certain means such as engineering and folic acid receptors. MSCs-Exo is an excellent carrier for chemotherapeutic agents and shows promising applications.